Renaissance Technologies's ACAD Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.45 M shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $30.93 M, representing 0.04% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 823,333 shares. Largest reduction occurred in Q1 2020, reducing 670,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2018 | +223,200 | New Buy | 223,200 | $15.27 |
| Q3 2018 | -50,900 | Reduce 22.80% | 172,300 | $20.76 |
| Q4 2018 | +425,500 | Add 246.95% | 597,800 | $16.17 |
| Q1 2019 | -597,800 | Sold Out | 597,800 | $0.00 |
| Q3 2019 | +85,800 | New Buy | 85,800 | $35.99 |
| Q4 2019 | +645,200 | Add 751.98% | 731,000 | $42.78 |
| Q1 2020 | -670,200 | Reduce 91.68% | 60,800 | $42.25 |
| Q2 2020 | +51,400 | Add 84.54% | 112,200 | $48.47 |
| Q3 2020 | +157,300 | Add 140.20% | 269,500 | $41.25 |
| Q4 2020 | -87,100 | Reduce 32.32% | 182,400 | $53.46 |
| Q1 2021 | +398,600 | Add 218.53% | 581,000 | $25.80 |
| Q2 2021 | -581,000 | Sold Out | 581,000 | $0.00 |
| Q1 2022 | +14,500 | New Buy | 14,500 | $24.21 |
| Q2 2022 | -14,500 | Sold Out | 14,500 | $0.00 |
| Q3 2022 | +37,700 | New Buy | 37,700 | $16.37 |
| Q4 2022 | +278,000 | Add 737.40% | 315,700 | $0.02 |
| Q1 2023 | -197,900 | Reduce 62.69% | 117,800 | $0.02 |
| Q2 2023 | +13,000 | Add 11.04% | 130,800 | $0.02 |
| Q3 2023 | -130,800 | Sold Out | 130,800 | $0.00 |
| Q4 2023 | +184,000 | New Buy | 184,000 | $31.31 |
| Q1 2024 | +389,800 | Add 211.85% | 573,800 | $18.49 |
| Q2 2024 | -97,800 | Reduce 17.04% | 476,000 | $16.25 |
| Q3 2024 | -72,800 | Reduce 15.29% | 403,200 | $15.38 |
| Q4 2024 | +823,333 | Add 204.20% | 1.23 M | $18.35 |
| Q1 2025 | +250,500 | Add 20.42% | 1.48 M | $16.61 |
| Q2 2025 | +70,699 | Add 4.79% | 1.55 M | $21.57 |
| Q3 2025 | -98,199 | Reduce 6.34% | 1.45 M | $21.34 |
Renaissance Technologies's ACADIA Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q2 2018, acquiring 223,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held ACADIA Pharmaceuticals Inc. (ACAD) for 30 quarters since Q2 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q4 2024, adding 1,226,533 shares worth $22.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,449,533 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $30.93 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.04% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 1,547,732 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.